Radius Health (NASDAQ: RDUS): Reiterating Buy Rating With Revised Price Target=$59.

RDUS

FDA approved Radius Health's (RDUS) Abaloparatide for the treatment of postmenopausal women at high risk of fracture last week. Abaloparatide has shown higher clinical efficacy to prevent vertebral fractures compared to both Forteo and Prolia in phase 3 trials. Also, it has shown statistically si...

FDA approved Radius Health's (RDUS) Abaloparatide for the treatment of postmenopausal women at high risk of fracture last week. Abaloparatide has shown higher clinical efficacy to prevent vertebral fractures compared to both Forteo and Prolia in phase 3 trials. Also, it has shown statistically si...

This article is only available to subscribers of Vasuda Healthcare Analytics
Learn more about Vasuda Healthcare Analytics